Publikationen in Zusammenarbeit mit Forschern von Hospital General Universitario Gregorio Marañón (11)

2024

  1. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1779-1789

  2. Thrombosis in breast cancer patients on cyclin-dependent kinase inhibitors: Survival impact and predictive factors - A study by the cancer and thrombosis group of the spanish society of medical oncology (SEOM)

    European Journal of Internal Medicine

2022

  1. Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial

    Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661

  2. Incidence, risk factors, and evolution of venous thromboembolic events in patients diagnosed with pancreatic carcinoma and treated with chemotherapy on an outpatient basis

    European Journal of Internal Medicine, Vol. 105, pp. 30-37

  3. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

    Breast, Vol. 66, pp. 77-84

2021

  1. The prognostic value of respiratory symptoms and performance status in ambulatory cancer patients and unsuspected pulmonary embolism; analysis of an international, prospective, observational cohort study

    Journal of Thrombosis and Haemostasis, Vol. 19, Núm. 11, pp. 2791-2800

2018

  1. Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/ HER2– advanced or metastatic breast cancer in Spain

    ClinicoEconomics and Outcomes Research, Vol. 10, pp. 773-790

2017

  1. Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM “El Álamo III” retrospective study

    PLoS ONE, Vol. 12, Núm. 10

2010

  1. Adjuvant docetaxel for high-risk, node-negative breast cancer

    New England Journal of Medicine, Vol. 363, Núm. 23, pp. 2200-2210

1994

  1. TRATAMIENTO DEL MELANOMA MALIGNO DISEMINADO. PAPEL DE LA HORMONOTERAPIA

    Oncologia, Vol. 17, Núm. 4, pp. 17-22

1992

  1. QUIMIOTERAPIA CON CISPLATINO, ADRIAMICINA, ETOPOSIDO E IFOSFAMIDA EN EL CARCINOMA MICROCITICO PULMONAR

    Medicina Clinica, Vol. 99, Núm. 8, pp. 289-293